Dienogest and estradiol and Leustatin injection
Determining the interaction of Dienogest and estradiol and Leustatin injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives. MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ. Cerner Multum, Inc. "Australian Product Information." O 0
Professional:ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with cladribine may reduce the efficacy of hormonal contraceptives. The mechanism has not been established. There are no clinical data regarding the use of cladribine with hormonal contraceptives.
MANAGEMENT: Although the clinical significance of this interaction is unknown, caution is advised when cladribine is prescribed concomitantly with hormonal contraceptives because of the potential to cause fetal harm. Women should avoid becoming pregnant during treatment with cladribine and for at least 6 months after the last dose in each treatment course. Women using hormonal contraceptives should add a barrier method during cladribine dosing and for at least 4 weeks after the last dose in each treatment cycle. In addition, male patients should take precautions to prevent pregnancy of their partner during cladribine dosing and for at least 6 months after the last dose in each treatment course.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
- Cerner Multum, Inc. "Australian Product Information." O 0
Generic Name: dienogest / estradiol
Brand name: Natazia
Synonyms: Estradiol and Dienogest
Generic Name: cladribine
Brand name: Leustatin, Mavenclad
Synonyms: Leustatin (injection), Leustatin
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dienogest and estradiol-Leva Set
- Dienogest and estradiol-Levacet
- Dienogest and estradiol-Levalbuterol
- Dienogest and estradiol-Levalbuterol HFA Aerosol
- Dienogest and estradiol-Levalbuterol inhalation
- Dienogest and estradiol-Levalbuterol Inhalation Aerosol
- Leustatin injection-Diethylene Triamine Penta-Acetic Acid
- Leustatin injection-Diethylpropion
- Leustatin injection-Diethylpropion Controlled-Release Tablets
- Leustatin injection-Diethylpropion Extended Release
- Leustatin injection-Diethylpropion Hydrochloride
- Leustatin injection-Diethylpropion Tablets